Nachrichten zur MEDIVIR AB Aktie

Medivir to present at the Pareto Securities Healthcare Conference

Stockholm, Sweden, September 16, 2024 — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for…

MEDIVIR AB – INTERIM REPORT JANUARY – JUNE 2024

“Our study shows a superior profile with the combination of fostrox and Lenvima in advanced liver cancer” April – June Financial summary…

Number of shares and votes in Medivir AB on 28 June 2024

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the number of shares and votes in Medivir has changed…

Issue, repurchase and reclassification of shares of series C and transfer of ordinary shares under LTIP 2024

In light of the incentive program adopted by the annual general meeting of Medivir AB (publ) (“Medivir”) on 7 May…

MEDIVIR AB – INTERIM REPORT JANUARY – MARCH 2024

”Preparations for the planned phase 2b study continue according to plan after the completed Type C meeting with the FDA,…

Notice of Annual General Meeting of Medivir AB (publ)

The shareholders of Medivir AB (publ), reg. no. 556238-4361, with its registered office in Huddinge, Stockholm, are hereby summoned to…

Number of shares and votes in Medivir AB on 31 January 2024

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the number of shares and votes in Medivir has…

HDAC Inhibitor Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

The prevalence of Cancer has been rising over the past few years, which prompts the growing demand for treatment options.…

Bulletin from Extraordinary General Meeting in Medivir AB (publ)

Today on 1 December 2023, Medivir AB (publ) (the “Company”) held an extraordinary general meeting in Stockholm, whereby the resolution…

Notice of Extraordinary General Meeting in Medivir AB (publ)

The shareholders in Medivir AB (publ) reg. no. 556238-4361 (the “Company”) are hereby convened to the extraordinary general meeting, which…

MEDIVIR AB – INTERIM REPORT JANUARY – SEPTEMBER 2023

“Updated data show that the combination fostrox + Lenvima® provides improved clinical efficacy compared to Lenvima study data alone in…

Medivir´s Partner Tango Therapeutics received FDA clearance to start the TNG348 phase 1/2 clinical study

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas…

Medivir to present at the Erik Penser Bank Company Event

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas…

Medivir AB reports 1H results

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

MEDIVIR AB - INTERIM REPORT JANUARY - JUNE 2023

STOCKHOLM, Aug. 18, 2023 /PRNewswire/ -- Continued strong momentum and promising signs of patient benefit in the combination study with…

MEDIVIR AB – INTERIM REPORT JANUARY – JUNE 2023

Continued strong momentum and promising signs of patient benefit in the combination study with fostrox and Lenvima[®] April – June Financial summary…

Promising tumor control for fostrox in combination with Lenvima in ongoing phase 2a study in HCC, 15th patient included

· Continued tumor control in the liver in 7 of the first 10 patients after three months of treatment …

Medivir partners with world-leading liver cancer experts in new Scientific Advisory Council

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas…

Medivir has completed the dose escalation part (phase 1b) of the 1b/2a study in HCC and focuses on the combination of fostrox and Lenvima

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas…

Medivir to present at the Redeye Growth Day

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas…

Change in the number of shares and votes in Medivir AB (publ)

STOCKHOLM, May 31, 2023 /PRNewswire/ -- Medivir AB (publ) ("Medivir") (Nasdaq Stockholm: MVIR) today announces that the number of shares…

Change in the number of shares and votes in Medivir AB (publ)

Stockholm – Medivir AB (publ) (“Medivir”) (Nasdaq Stockholm: MVIR) today announces that the number of shares and votes in Medivir…

Medivir to present at the ABGSC Life Science Summit

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas…

Issue, repurchase and reclassification of shares of series C and transfer of ordinary shares under LTIP 2023

In light of the incentive program adopted by the annual general meeting of Medivir AB (publ) (“Medivir”) on 4 May…

XFRA : Deletion of Instruments from Boerse Frankfurt - 15.05.2023

The following instruments on Boerse Frankfurt do have their last trading day on 15.05.2023. Die folgenden Instrumente in Boerse Frankfurt haben…

Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: Anmerkungen SE0000273294 Medivir AB 15.05.2023 SE0020181014 Medivir AB 16.05.2023 Tausch 1:1 US9840155033 Xenetic Biosciences Inc. 15.05.2023 US9840156023 Xenetic Biosciences Inc. 16.05.2023 Tausch 10:1 GRS314003005 Mig Holdings S.A. 15.05.2023 GRS314003013 Mig Holdings S.A. 16.05.2023 Tausch 1:1 GB00BN0SMB92 Capricorn Energy PLC 15.05.2023 GB00BQ98V038 Capricorn Energy…

Resolutions at the Annual General Meeting in Medivir on 4 May 2023

STOCKHOLM, May 4, 2023 /PRNewswire/ -- Medivir Aktiebolag (publ) held its annual general meeting today on 4 May 2023. The…

Resolutions at the Annual General Meeting in Medivir on 4 May 2023

Medivir Aktiebolag (publ) held its annual general meeting today on 4 May 2023. The annual general meeting was held by…

MEDIVIR AB - INTERIM REPORT JANUARY - MARCH 2023

HUDDINGE, Sweden, April 27, 2023 /PRNewswire/ -- "Thanks to the strong interest from clinicians and patients, we were able to…

MEDIVIR AB – INTERIM REPORT JANUARY – MARCH 2023

“Thanks to the strong interest from clinicians and patients, we were able to swiftly dose the first patients in the…

Medivir presents new data at AACR showing significantly improved antitumor efficacy in non-clinical tumor models with fostrox in triple combination

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas…

Medivir 2022 Annual Report published

STOCKHOLM, April 4, 2023 /PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR) today announces that the Annual Report for 2022 now…

Medivir 2022 Annual Report published

Stockholm, Sweden - Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Annual Report for 2022 now is available at…

Notice of Annual General Meeting of Medivir AB (publ)

STOCKHOLM, March 31, 2023 /PRNewswire/ -- The shareholders of Medivir AB (publ), reg. no. 556238-4361, with its registered office in…

Notice of Annual General Meeting of Medivir AB (publ)

The shareholders of Medivir AB (publ), reg. no. 556238-4361, with its registered office in Huddinge, Stockholm, are hereby summoned to…

Medivir to present data on additive efficacy of fostrox in triple combination with anti-PD1 and kinase inhibitor in nonclinical tumor models at AACR

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas…

dpa-AFX ProFeed